News

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts

STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma     SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro Biopharma’s antibody drug conjugate targeting the CD74 cell surface protein in hematologic B-cell malignancies, has been…

SutroVax Announces Closing of $64M via Series B Financing

Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of a $60 million Series B financing. The financing was led by new investors…

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma

SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001, an antibody drug conjugate, or ADC, that targets CD74, a protein highly expressed in B-cell malignancies.  STRO-001 demonstrated efficient cell…

BioTech Nation Radio with CEO Bill Newell

NPR and BioTech Nation interview Sutro’s CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the conversation as Bill describes Sutro’s discovery and development efforts combining targeted warheads and ADC’s in our ground breaking efforts.  …

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma

SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies.  The ADCs demonstrated efficient cell killing in multiple malignant…